[Federal Register Volume 61, Number 139 (Thursday, July 18, 1996)]
[Notices]
[Page 37486]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 96M-0233]
Infinitech Inc.; Premarket Approval of PerfluoronTM (Highly
Purified Perfluoro-n-Octane Liquid)
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing its
approval of the application by Infinitech Inc., Chesterfield, MO, for
premarket approval, under the Federal Food, Drug, and Cosmetic Act (the
act), of Perfluoron (highly purified perfluoro-n-octane liquid). After
reviewing the recommendation of the Ophthalmic Devices Panel, FDA's
Center for Devices and Radiological Health (CDRH) notified the
applicant, by letter of February 29, 1996, of the approval of the
application.
DATES: Petitions for administrative review by August 19, 1996.
ADDRESSES: Written requests for copies of the summary of safety and
effectiveness data and petitions for administrative review, to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: James F. Saviola, Center for Devices
and Radiological Health (HFZ-460), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-594-1744.
SUPPLEMENTARY INFORMATION: On April 28, 1995, Infinitech Inc.,
Chesterfield, MO 63005, submitted to CDRH an application for premarket
approval of Perfluoron (highly purified perfluoro-n-octane liquid). The
device, a perfluorocarbon liquid, is an intraoperative tool indicated
for use during vitreoretinal surgery in patients with primary or
recurrent retinal detachment which is complicated by penetrating ocular
trauma, giant retinal tear(s) or proliferative vitreoretinopathy. -
On October 19, 1995, the Ophthalmic Devices Panel of the Medical
Devices Advisory Committee, an FDA advisory committee, reviewed and
recommended approval of the application. On February 29, 1996, CDRH
approved the application by a letter to the applicant from the Director
of the Office of Device Evaluation, CDRH.
A summary of the safety and effectiveness data on which CDRH based
its approval is on file in the Dockets Management Branch (address
above) and is available from that office upon written request. Requests
should be identified with the name of the device and the docket number
found in brackets in the heading of this document.
Opportunity for Administrative Review
Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any
interested person to petition, under section 515(g) of the act, for
administrative review of CDRH's decision to approve this application. A
petitioner may request either a formal hearing under part 12 (21 CFR
part 12) of FDA's administrative practices and procedures regulations
or a review of the application and CDRH's action by an independent
advisory committee of experts. A petition is to be in the form of a
petition for reconsideration under Sec. 10.33(b) (21 CFR 10.33(b)). A
petitioner shall identify the form of review requested (hearing or
independent advisory committee) and shall submit with the petition
supporting data and information showing that there is a genuine and
substantial issue of material fact for resolution through
administrative review. After reviewing the petition, FDA will decide
whether to grant or deny the petition and will publish a notice of its
decision in the Federal Register. If FDA grants the petition, the
notice will state the issue to be reviewed, the form of the review to
be used, the persons who may participate in the review, the time and
place where the review will occur, and other details.
Petitioners may, at any time on or before August 19, 1996, file
with the Dockets Management Branch (address above) two copies of each
petition and supporting data and information, identified with the name
of the device and the docket number found in brackets in the heading of
this document. Received petitions may be seen in the office above
between 9 a.m. and 4 p.m., Monday through Friday.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10)
and redelegated to the Director, Center for Devices and Radiological
Health (21 CFR 5.53).
Dated: June 5, 1996.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and
Radiological Health.
[FR Doc. 96-18283 Filed 7-17-96; 8:45 am]
BILLING CODE 4160-01-F
